Skip to main content
ISPRM 2026 Main banner
Final Program


Final Congress Guide

Engineering and Technology

500 Section - Utilization of the Cionic Neural Sleeve in Multiple Sclerosis -A Retrospective Study

Wednesday, May 20, 2026
6:00 PM - 7:30 PM PT

    Presenting Author/Autor expositor(s)

  • AM

    Angeli Mayadev, MD

    Physician
    Swedish MS Center- Neuroscience Institute
    Seattle, Washington, United States

    • Co-Author/Coautor(s)

  • KK

    Kimberly Kobata, PT

    PT
    Swedish MS Center- Neuroscience Institute
    Seattle, Washington, United States

  • KF

    Kathryn Fong, MD

    Physician
    Swedish MS Center- Neuroscience Institute
    Seattle, Washington, United States

  • SC

    Shih Ting Chiu, PhD

    Biostatistician
    Swedish MS Center- Neuroscience Institute
    Seattle, Washington, United States

  • PR

    Pavle Repovic, MD

    Physician
    Swedish MS Center- Neuroscience Institute
    Seattle, Washington, United States

Objectives :

This study explores the experiences and outcomes of multiple sclerosis (MS) patients who trialed the Neural Sleeve, a wearable device designed to enhance walking. 


  • Primary Objective: Assess the utilization and clinical factors influencing the adoption of the Sleeve, focusing on correlations between age, MS type, disease duration, baseline 10-meter walk test (10MW), and the Expanded Disability Status Scale (EDSS).

  • Secondary Objectives: Investigate barriers to obtaining the device, specifically non-effectiveness and financial constraints.



Design:

Data from the electronic medical records of 29 patients that trialed the Sleeve between 4/1/24 -6/25/25. Patients were grouped into those who elected to obtain the device (adopters) and those who did not (non-adopters). Adoption rates correlated with the above clinical parameters.
A non-parametric analytical approach was employed to accommodate the small sample size.

Results:

 Among the 29 patients who trialed the Sleeve, 16 (62%) adopted it. Of the 13 non-adopters, non-efficacy (70%) was cited as the more common reason than financial constraints (30%). The correlation analysis between adoption rates and clinical parameters was conducted using the Kruskal-Wallis rank sum test. Here are the findings: 






  • Age: ≤60 showed a median 10MWT of 0.90 (0.65-1.06), >60 had a median of 0.87 (0.57-1.09) (p=0.8). 








  • MS Subtype: Primary progressive (pp) patients had a median 10MWT of 1.07, relapsing-remitting (rr) patients had 0.95 (0.87-1.08), and secondary progressive (sp) patients had 0.77 (0.59-1.06) (p=0.4).  








  • Disease Duration: 1-10 years was correlated with a median 10MWT of 1.00 (0.87-1.08), 11-20 years with 0.99 (0.93-1.17), 21-30 years with 0.65 (0.57-1.23), and over 30 years with 0.41 (0.17-0.89) (p=0.065).  






EDSS:  ≤6 had a median 10MWT of 0.96 (0.74-1.08), scores >6 had 0.59 (0.18-1.07) (p=0.13)





 



Conclusion:

62% adopted it for long-term use. Non-efficacy (70%) and financial constraints (30%) limited adoption.
While most correlations were not statistically significant, the trend observed for disease duration (p=0.065) suggests further investigation may beneficial.